Professor Mimi Tang
National Allergy Centre of Excellence Food Allergy Stream co-Chair
- Allergy Immunology Group Leader and Director of the Allergy Translation Centre, Murdoch Children’s Research Institute
- Professorial Fellow, Department of Paediatrics, the University of Melbourne
- Consultant Immunologist Allergist, Royal Children’s Hospital, Melbourne
- Chief Investigator, Centre for Food & Allergy Research
A global leader in allergy and immunology, with more than 30 years’ experience, Professor Mimi Tang has authored more than 300 peer reviewed journal articles, invited reviews, book chapters, and a book. She is recognised internationally for her research achievements, investigating immune mechanisms of allergic disease, the role of probiotics and gut microbiota in modulating immune responses, and for discovering a highly effective world-first remission treatment for food allergy.
Prof Tang is Head of the Allergy Immunology Group and Director of the Allergy Translation Centre at the Murdoch Children’s Research Institute (MCRI). She is a Professorial Fellow in the University of Melbourne Department of Paediatrics and Consultant Immunology Allergist at the Royal Children’s Hospital, Melbourne.
Prof Tang’s research investigates the basic immunological mechanisms underlying allergic disease pathogenesis. She collaborates on longitudinal cohort studies, including the Barwon Infant Study, HealthNuts, EarlyNuts and SchoolNuts, and on prevention trials, including PEBBLES and VITALITY. She is a Chief Investigator for the NHMRC-funded Centre for Food & Allergy Research, hosted at MCRI.
Prof Tang was named on the Highly Cited Researchers 2022 list from Clarivate, which celebrates researchers ranked in the top one per cent in the Web of Science citation index.
RECENT PUBLICATIONS
Revisiting the Atopic March: Current Evidence. American Journal of Respiratory and Critical Care Medicine. Oct 2022
Measuring the Impact of Food Immunotherapy on Health-Related Quality of Life in Clinical Trials. Frontiers in Allergy. Jul 2022
Association Between Earlier Introduction of Peanut and Prevalence of Peanut Allergy in Infants in Australia. JAMA. Jul 2022
Household size, T regulatory cell development, and early allergic disease: a birth cohort study. Pediatric Allergy and Immunology. Jun 2022
Remission of peanut allergy is associated with rewiring of allergen‐driven T helper 2‐related gene networks. Allergy. May 2022
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. The Lancet Child & Adolescent Health. Feb 2022
SELECTED STUDIES
- Peanut Allergy (PPOIT001, PPOIT002, PPOIT003, PPOIT003 LT)
- Egg Allergy (PrEMO, PEAT)
- Milk Allergy (PrEMO)
- TreEat Study
- PEBBLES Study
- VITALITY Trial
- HealthNuts
- EarlyNuts
- SchoolNuts
- Barwon Infant study (BIS)
KEY RESOURCES
Proudly in partnership with the National Allergy Council and allergy organisations
